OPKO Health (NASDAQ:OPK) Stock Rating Lowered by Wall Street Zen

OPKO Health (NASDAQ:OPK) was downgraded by equities researchers at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued to investors on Saturday.

Other equities analysts also recently issued research reports about the company. Barrington Research reiterated an “outperform” rating and set a $2.25 price target on shares of OPKO Health in a report on Thursday, October 30th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of OPKO Health in a report on Wednesday, October 8th. JPMorgan Chase & Co. initiated coverage on shares of OPKO Health in a report on Thursday, November 20th. They issued a “neutral” rating on the stock. Finally, Jefferies Financial Group reissued a “hold” rating and set a $1.60 target price (down previously from $2.00) on shares of OPKO Health in a research report on Thursday, October 30th. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $2.28.

OPKO Health Price Performance

NASDAQ OPK opened at $1.38 on Friday. OPKO Health has a fifty-two week low of $1.11 and a fifty-two week high of $2.04. The stock’s 50-day moving average is $1.40 and its two-hundred day moving average is $1.38. The firm has a market cap of $1.06 billion, a P/E ratio of -5.52 and a beta of 1.34. The company has a debt-to-equity ratio of 0.25, a current ratio of 3.70 and a quick ratio of 3.32.

OPKO Health (NASDAQ:OPK) last issued its quarterly earnings data on Wednesday, October 29th. The biotechnology company reported $0.03 EPS for the quarter, beating analysts’ consensus estimates of ($0.02) by $0.05. OPKO Health had a negative return on equity of 13.67% and a negative net margin of 28.10%.The business had revenue of $151.67 million for the quarter, compared to analyst estimates of $165.74 million. During the same quarter in the prior year, the firm posted $0.03 EPS. The firm’s revenue for the quarter was down 12.6% on a year-over-year basis. On average, analysts anticipate that OPKO Health will post -0.25 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Phillip Md Et Al Frost purchased 580,000 shares of the stock in a transaction that occurred on Friday, November 21st. The shares were purchased at an average cost of $1.33 per share, for a total transaction of $771,400.00. Following the completion of the purchase, the chief executive officer directly owned 216,706,448 shares of the company’s stock, valued at approximately $288,219,575.84. The trade was a 0.27% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders bought 1,843,300 shares of company stock worth $2,421,491 over the last 90 days. 49.69% of the stock is owned by company insiders.

Institutional Trading of OPKO Health

Institutional investors have recently modified their holdings of the company. Caprock Group LLC bought a new stake in shares of OPKO Health during the third quarter valued at approximately $26,000. Swiss Life Asset Management Ltd acquired a new stake in OPKO Health during the third quarter worth $30,000. GM Advisory Group LLC bought a new stake in OPKO Health in the 1st quarter valued at $33,000. Savant Capital LLC acquired a new position in shares of OPKO Health in the 3rd quarter valued at $33,000. Finally, Arrow Financial Corp bought a new position in shares of OPKO Health during the 3rd quarter worth about $39,000. Institutional investors and hedge funds own 64.63% of the company’s stock.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.